Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. (From -To) 19 Jan 04 -18 Jan 07
REPORT DATE (DD-MM-YYYY)
01-02-2007
REPORT TYPE
Final
DATES COVERED
TITLE AND SUBTITLE
Involvement and Regulation of Heparanase in Prostate Cancer
ABSTRACTImprovement in prostate cancer patient survival requires the identification of new therapeutic targets, based on a detailed understanding of the biologic mechanisms involved in metastatic dissemination and growth in bone and other target organs. Heparanase (HPSE) is a predominant mammalian enzyme that cleaves heparan sulfate, the main polysaccharide component of the extracellular matrix (ECM). The role of HPSE in sustaining the pathology of malignant tumors is being extensively studied during the last decade. The link between HPSE and prostate carcinoma progression remains less investigated and was disputed in recent publications, favoring or opposing involvement of the enzyme. Here we report that HPSE directly contributes to the prostate tumor take and growth in bone, as well as to its ability to metastasize to distant organs. Inhibitory strategies designed in the course of the research are hoped to develop into effective anti-cancer therapeutic modalities. Knowledge gained on the regulatory machinery of heparanase promoter is of high significance, as a part of general effort to define the exact molecular mechanisms of heparanasedriven prostate tumorigenesis. In summary, our results suggest that in prostate tumorigenesis HPSE may become important molecular marker in clinical decision-making process for prostate tumor patients, as well as a target for intervention.
SUBJECT TERMS